JP2013514992A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013514992A5 JP2013514992A5 JP2012544884A JP2012544884A JP2013514992A5 JP 2013514992 A5 JP2013514992 A5 JP 2013514992A5 JP 2012544884 A JP2012544884 A JP 2012544884A JP 2012544884 A JP2012544884 A JP 2012544884A JP 2013514992 A5 JP2013514992 A5 JP 2013514992A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequences
- nos
- antibody
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28817109P | 2009-12-18 | 2009-12-18 | |
| US61/288,171 | 2009-12-18 | ||
| PCT/US2010/060992 WO2011075636A2 (en) | 2009-12-18 | 2010-12-17 | Wise binding agents and epitopes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013514992A JP2013514992A (ja) | 2013-05-02 |
| JP2013514992A5 true JP2013514992A5 (enExample) | 2014-02-06 |
Family
ID=43640272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012544884A Withdrawn JP2013514992A (ja) | 2009-12-18 | 2010-12-17 | Ｗｉｓｅ結合剤およびエピトープ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120288507A1 (enExample) |
| EP (1) | EP2512600A2 (enExample) |
| JP (1) | JP2013514992A (enExample) |
| AR (1) | AR079572A1 (enExample) |
| AU (1) | AU2010330794A1 (enExample) |
| CA (1) | CA2784093A1 (enExample) |
| MX (1) | MX2012007055A (enExample) |
| TW (1) | TW201132353A (enExample) |
| UY (1) | UY33124A (enExample) |
| WO (1) | WO2011075636A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501531B2 (en) | 2013-03-13 | 2019-12-10 | Prothena Biosciences Limited | Tau immunotherapy |
| WO2015187519A1 (en) * | 2014-06-06 | 2015-12-10 | Merck Sharp & Dohme Corp. | Tslp assay |
| MX2018010295A (es) * | 2016-02-26 | 2019-06-06 | Inst Nat Sante Rech Med | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. |
| MX2018013386A (es) | 2016-05-02 | 2019-02-28 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
| MY198194A (en) | 2016-05-02 | 2023-08-09 | Prothena Biosciences Ltd | Antibodies Recognizing Tau |
| PT3452507T (pt) | 2016-05-02 | 2022-12-20 | Prothena Biosciences Ltd | Imunoterapia anti-tau |
| WO2018027149A1 (en) * | 2016-08-04 | 2018-02-08 | University Of Miami | Methods of treating alport syndrome |
| JP7066696B2 (ja) * | 2016-10-11 | 2022-05-13 | アジェナス インコーポレイテッド | 抗ｌａｇ－３抗体及びその使用方法 |
| AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CN110944661A (zh) | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| KR102784294B1 (ko) | 2017-05-02 | 2025-03-19 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| EP3774921A4 (en) * | 2018-04-03 | 2022-01-05 | Dragonfly Therapeutics, Inc. | ANTIBODY VARIABLE DOMAINS AGAINST DLL3 AND USE OF IT |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| JP7630834B2 (ja) | 2019-03-03 | 2025-02-18 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| CN114364694B (zh) * | 2019-07-12 | 2024-05-10 | 国立大学法人京都大学 | 靶向usag-1分子的用于牙齿再生治疗的中和抗体 |
| US12486321B2 (en) | 2020-01-21 | 2025-12-02 | Tavotek Biotechnology (Jiangsu) Co., Ltd | Agents that interfere with IL-1BETA receptor signalling |
| JP7512394B2 (ja) | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| CN112180099B (zh) * | 2020-09-15 | 2022-07-29 | 江南大学附属医院 | 子宫内膜异位症血清标志物的应用 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| JPS58117537A (ja) | 1982-01-06 | 1983-07-13 | Toray Ind Inc | 感光性樹脂組成物 |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| CA2220912A1 (en) | 1995-06-05 | 1996-12-12 | Gregg A. Hastings | Human ccn-like growth factor |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| JP2003534813A (ja) | 2000-06-01 | 2003-11-25 | アムジェン インコーポレーテッド | シスチンノットポリペプチド：ｃｌｏａｋｅｄ−２分子およびその使用 |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7585501B2 (en) * | 2002-06-14 | 2009-09-08 | Stowers Institute For Medical Research | Compositions and methods for treating kidney disease |
| AU2008330125B2 (en) | 2007-11-21 | 2012-11-22 | Amgen Inc. | Wise binding antibodies and epitopes |
-
2010
- 2010-12-17 US US13/516,161 patent/US20120288507A1/en not_active Abandoned
- 2010-12-17 MX MX2012007055A patent/MX2012007055A/es not_active Application Discontinuation
- 2010-12-17 JP JP2012544884A patent/JP2013514992A/ja not_active Withdrawn
- 2010-12-17 CA CA2784093A patent/CA2784093A1/en not_active Abandoned
- 2010-12-17 EP EP10801508A patent/EP2512600A2/en not_active Withdrawn
- 2010-12-17 WO PCT/US2010/060992 patent/WO2011075636A2/en not_active Ceased
- 2010-12-17 AU AU2010330794A patent/AU2010330794A1/en not_active Abandoned
- 2010-12-17 TW TW099144615A patent/TW201132353A/zh unknown
- 2010-12-20 AR ARP100104799A patent/AR079572A1/es unknown
- 2010-12-20 UY UY0001033124A patent/UY33124A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013514992A5 (enExample) | ||
| ME02484B (me) | Ljudska antitela visokog afiniteta prema ljudskom angiopoietinu-2 | |
| JP2013534812A5 (enExample) | ||
| CN104114574B (zh) | 结合人补体c5的多肽 | |
| TR201817932T4 (en) | ANTIBODIES THAT BIND STAPHYLOCOCCUS AUREUS ALPHA TOXIN SPECIFICALLY AND METHODS OF USE | |
| JP2010535032A5 (enExample) | ||
| JP2021530223A5 (enExample) | ||
| PH12013501397A1 (en) | Ligands that bind tgf-beta receptor ii | |
| RU2534564C3 (ru) | Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii | |
| JP2019514998A5 (enExample) | ||
| JP2017500018A5 (enExample) | ||
| WO2013184960A3 (en) | Chimeric fibroblast growth factor 23 proteins and methods of use | |
| JP2013543384A5 (enExample) | ||
| JP2010524466A5 (enExample) | ||
| MX342291B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| JP2018511327A5 (enExample) | ||
| RU2015111341A (ru) | Композиции антитела и белка | |
| RU2013135175A (ru) | Фармацевтическая композиция комплекса антитела против дигоксигенина и дигоксигенина, конъюгированного с пептидом | |
| RU2009133789A (ru) | Способы лечения глазных болезней | |
| RU2021124437A (ru) | Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| JP2017113019A5 (enExample) | ||
| JP2010506596A5 (enExample) | ||
| JP2012505912A5 (enExample) | ||
| JP2017537084A5 (enExample) |